Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy.
Alterations in the balance of K-Na-2Cl cotransporter (NKCC1) and Na-Cl cotransporter (KCC2) activity may cause depolarizing effect of γ-aminobutyric Acid (GABA), and contribute to epileptogenesis in human temporal lobe epilepsy. NKCC1 facilitates accumulation of chloride inside neurons and favors depolarizing responses to GABA. In the current pilot study we provide the first documented look at efficacy of bumetanide, a specific NKCC1 antagonist, on reduction of seizure frequency in adult patients with temporal lobe epilepsy. According to our results, seizure frequency was reduced considerably in these patients. Furthermore, epileptiform discharges decreased in two of our patients. If the efficacy of bumetanide is proven in large scale studies, it can be used as a supplemental therapy in temporal lobe epilepsy.
Cellular and Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Sanaz
S
Eftekhari
Jafar
J
Mehvari Habibabadi
Massoumeh
M
Najafi Ziarani
Seyed Sohrab
SS
Hashemi Fesharaki
Marzieh
M
Gharakhani
Hossein
H
Mostafavi
Mohammad Taghi
MT
Joghataei
Nahid
N
Beladimoghadam
Elham
E
Rahimian
Mahmoud Reza
MR
Hadjighassem
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002034:Bumetanide / Q000627:therapeutic use*; D004569:Electroencephalography; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D012640:Seizures / Q000188:drug therapy; D016896:Treatment Outcome
D000927:Anticonvulsants; D002034:Bumetanide